Evidence map›Paper›PMID 33005892›Full record

ArticleBrain communications2020

Gut dysbiosis in Huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes.

Cory I Wasser, Emily-Clare Mercieca, Geraldine Kong, Anthony J Hannan, Sonja J McKeown, Yifat Glikmann-Johnston, Julie C Stout

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 187 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cory I WasserAgeing and Neurodegeneration Program, School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0002-1830-2862
Emily-Clare MerciecaAgeing and Neurodegeneration Program, School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0002-8162-0679
Geraldine KongFlorey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0001-9277-8650
Anthony J HannanFlorey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0001-7532-8922
Sonja J McKeownDepartment of Anatomy & Developmental Biology, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0002-7318-116X
Yifat Glikmann-JohnstonAgeing and Neurodegeneration Program, School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0002-6128-7768
Julie C StoutAgeing and Neurodegeneration Program, School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, Victoria 3800, Australia.ORCID 0000-0001-9637-8590
Monash University · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease is characterized by a triad of motor, cognitive and psychiatric impairments, as well as unintended weight loss. Although much of the research has focused on cognitive, motor and psychiatric symptoms, the extent of peripheral pathology and the relationship between these factors, and the core symptoms of Huntington's disease, are relatively unknown. Gut microbiota are key modulators of communication between the brain and gut, and alterations in microbiota composition (dysbiosis) can negatively affect cognition, behaviour and affective function, and may be implicated in disease progression. Furthermore, gut dysbiosis was recently reported in Huntington's disease transgenic mice. Our main objective was to characterize the gut microbiome in people with Huntington's disease and determine whether the composition of gut microbiota are significantly related to clinical indicators of disease progression. We compared 42 Huntington's disease gene expansion carriers, including 19 people who were diagnosed with Huntington's disease (Total Functional Capacity > 6) and 23 in the premanifest stage, with 36 age- and gender-matched healthy controls. Participants were characterized clinically using a battery of cognitive tests and using results from 16S V3 to V4 rRNA sequencing of faecal samples to characterize the gut microbiome. For gut microbiome measures, we found significant differences in the microbial communities (beta diversity) based on unweighted UniFrac distance (

Indexed as

cognitive impairmentgut–brain axisgut microbiomeHuntington’s diseaseneurodegenerative disease

Identifiers

PMID33005892
PMCPMC7519724
OpenAlexW3045452138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.